Linked Articles To view the original paper by Mani et al. visit http://dx.doi.org/10.1111/j.1476-5381.2011.01273.x and to view the reply to this letter visit http://dx.doi.org/10.1111/j.1476-5381.2011.01457.x
Letter to the Editor re Mani et al.
Article first published online: 22 AUG 2011
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society
British Journal of Pharmacology
Volume 164, Issue 2, pages 250–251, September 2011
How to Cite
Chadha, P. S., Greenwood, I. A., Zhong, X. Z. and Cole, W. C. (2011), Letter to the Editor re Mani et al. British Journal of Pharmacology, 164: 250–251. doi: 10.1111/j.1476-5381.2011.01454.x
- Issue published online: 22 AUG 2011
- Article first published online: 22 AUG 2011
- Accepted manuscript online: 26 APR 2011 03:48AM EST
To the Editor:
We have read with interest the recent article published by the British Journal of Pharmacology entitled ‘Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery’ (Mani et al., 2011). The study adds to a mounting body of evidence suggesting a pivotal role for KCNQ (Kv7) channels in regulating vascular tone and more particularly cerebral blood flow. Mani et al. (2011) showed that a known Kv7 activator flupirtine, as well as celecoxib, a type 2 cyclooxygenase -specific inhibitor clinically used as an anti-inflammatory that has recently been shown to also stimulate Kv7 channels (Brueggemann et al., 2009), relaxed 5HT-contracted basilar arteries and increased voltage-gated potassium currents in isolated myocytes.
Due to the relative infancy of the vascular KCNQ field, it is important that previous literature on this topic is adequately represented. Since the initial discovery in mouse portal vein myocytes (Ohya et al., 2003), KCNQ gene expression has been described in range of rodent blood vessels including portal vein, aorta, carotid, pulmonary and mesenteric arteries (Yeung et al., 2007; Mackie et al., 2008; Joshi et al., 2009; Zhong et al., 2010a) as well as human blood vessels (Ng et al., 2011) where products of KCNQ1, KCNQ4 and KCNQ5 predominate. In addition, a functional role for Kv7 channels in controlling vascular tone development has been identified using Kv7 channel blockers, which inhibit endogenous K+ currents, depolarize vascular smooth muscle and increase contractility (Yeung and Greenwood, 2005; Mackie et al., 2008; Joshi et al., 2009; Zhong et al., 2010a; Ng et al., 2011). This has been corroborated by the observation that agents such as the anticonvulsant retigabine, acrylamide S-1 and maxiprost, which activate Kv7.2–7.5 in overexpression systems, also enhance endogenous K+ in various vascular myocytes (Mackie et al., 2008; Yeung et al., 2008; Joshi et al., 2009; Zhong et al., 2010a) and relax pre-contracted vessels (Yeung et al., 2007; Mackie et al., 2008; Yeung et al., 2008; Joshi et al., 2009; Zhong et al., 2010a; Ng et al., 2011). Hence, the work by Mani et al. (2011) represents an addition to the burgeoning data showing Kv7 channels to be key regulators of vascular tone.
Much of the basilar artery data presented in Mani et al. confirm the observations made by Zhong et al. (2010a) who utilized extensive q-PCR, immunocytochemistry, isobaric myography and single-cell electrophysiology to characterise the importance of KCNQ channels in the rat middle cerebral artery. The impact of both sets of data is considerably enhanced when the reader fully appreciates that KCNQ channels contribute to control of contraction in conduit and myogenic resistance cerebral vessels and represent an important potential therapeutic target for the treatment of vascular disease. However, one note of caution raised by Zhong et al. (2010a) was ignored by Mani et al. (2011). Similar to previous studies on various vascular smooth muscles (Yeung and Greenwood, 2005; Yeung et al., 2007; Mackie et al., 2008; Joshi et al., 2009), Panels A and B of figure 3 in Mani et al. (2011) show that 10 µM XE991 evoked depolarization of isolated basilar arterial myocyte artery and constriction of intact basilar arteries. The authors concluded that this may be attributed to the inhibition of Kv7 channels. However, Zhong et al. (2010a) showed that XE991 completely suppressed native Kv currents of rat middle cerebral arterial myocytes and inhibited heterologously expressed Kv1.2/ Kv1.5 and Kv2.1/ Kv9.3 channels that also contribute to the native Kv current and control of membrane potential in these cells (Albarwani et al., 2003; Chen et al., 2006; Zhong et al., 2010b). Thus, while XE991 is an effective blocker of KCNQ-encoded K+ channels, caution should be exercised in the interpretation of experiments employing this agent, as it may have additional effects beyond specific blockade of Kv7 channels.
This letter should not be viewed as a negative comment on the data in Mani et al. who have contributed significantly to this nascent research field. On the contrary, we hope it emphasizes the perspective in which the article resides and provides further sources of information for this important and emerging aspect of vascular biology.
- 2003). Voltage-gated K+ channels in rat small cerebral arteries: molecular identity of the functional channels. J Physiol 551: 751–763. , , , , , et al. (
- 2009). Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 76: 1053–1061. , , , , (
- 2006). Key role of Kv1 channels in vasoregulation. Circ Res 99: 53–60. , , , , (
- 2009). KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther 329: 368–376. , , , , (
- 2008). Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475–483. , , , , , et al. (
- 2011). Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br J Pharmacol 164: 237–249. , , , (
- 2011). Expression and function of the K+ channel KCNQ genes in human arteries. Br J Pharmacol 162: 42–53. , , , , , et al. (
- 2003). Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res 92: 1016–1023. , , , (
- 2005). Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol 146: 585–595. , (
- 2007). Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 151: 758–770. , , , , , et al. (
- 2008). Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br J Pharmacol 155: 62–72. , , , (
- 2010b). Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter. J Physiol 588: 4519–4537. , , , , , et al. (
- 2010a). Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 588: 3277–3293. , , , , , et al. (